Advanced Life Sciences Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Advanced Life Sciences Holdings, Inc.
Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets
Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.
Alvotech Links Up With Polifarma On Proposed Eylea Biosimilar
Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.
GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform
Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.
L’Oréal Plans Largest Deal: $2.52Bn For Aesop
L’Oréal plans to acquire Australian luxury beauty brand Aesop from Natura & Co. in third quarter, subject to regulatory approvals, marking its biggest acquisition to date.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.